Re: Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients with Intermediate- or Poor-Risk Germ Cell Tumors Editorial Comment

被引：0
|
作者：
Richie, Jerome P.
机构：
来源：
JOURNAL OF UROLOGY | 2017年 / 198卷 / 02期
关键词：
D O I：
10.1016/j.juro.2017.05.023
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：257 / 257
页数：1
相关论文
共 50 条
  • [31] Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival
    McCaffrey, JA
    Mazumdar, M
    Bajorin, DF
    Bosl, GJ
    Vlamis, V
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (07) : 2559 - 2563
  • [32] Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors
    Kondagunta, GV
    Bacik, J
    Donadio, A
    Bajorin, D
    Marion, S
    Sheinfeld, J
    Bosl, GJ
    Motzer, RJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (27) : 6549 - 6555
  • [33] TREATMENT OF POOR-RISK GERM-CELL TUMORS WITH HIGH-DOSE CISPLATIN AND ETOPOSIDE COMBINED WITH BLEOMYCIN
    DAUGAARD, G
    RORTH, M
    ANNALS OF ONCOLOGY, 1992, 3 (04) : 277 - 282
  • [34] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB plus IPILIMUMAB VERSUS SUNITINIB IN THE FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC INTERMEDIATE- OR POOR-RISK RENAL CELL CARCINOMA IN SPAIN
    Polanco Sanchez, C.
    Perez-Alcantara, F.
    May, J.
    Gooden, K. M.
    Malcolm, B.
    Arranz, J. A.
    Duran, I
    Garcia-Donas, J.
    Gallardo, E.
    Lainez, N.
    Maroto, P.
    Valderrama, B. P.
    Puente, J.
    Vazquez, S.
    Van de Wetering, G.
    van Carroll, Smith L. E.
    VALUE IN HEALTH, 2019, 22 : S466 - S466
  • [35] ETOPOSIDE, CISPLATIN, BLEOMYCIN, AND CYCLOPHOSPHAMIDE (ECBC) AS 1ST-LINE CHEMOTHERAPY FOR POOR-RISK NONSEMINOMATOUS GERM-CELL TUMORS
    GERL, A
    CLEMM, C
    HENTRICH, M
    HARTENSTEIN, R
    WILMANNS, W
    ACTA ONCOLOGICA, 1993, 32 (05) : 541 - 546
  • [36] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
  • [37] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Esra Çakar
    César Oniangue-Ndza
    Ralph P. Schneider
    Sven L. Klijn
    Ursula M. Vogl
    Christian Rothermundt
    Jessica R. May
    PharmacoEconomics - Open, 2023, 7 : 567 - 577
  • [38] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
  • [39] Vinorelbine, ifosfamide and cisplatin as first-line treatment in patients with inoperable non-small cell lung cancer
    Montalar, J
    Morales, S
    Maestu, I
    Camps, C
    Vadell, C
    García, R
    Yuste, AL
    Torregrosa, D
    Segura, A
    LUNG CANCER, 2001, 34 (02) : 305 - 311
  • [40] Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients
    Haioun, C
    Mounier, N
    Quesnel, B
    Morel, P
    Rieux, C
    Beaujean, F
    Marolleau, JP
    Belhadj, K
    Simon, D
    Gaulard, P
    Lepage, E
    Gisselbrecht, C
    Reyes, F
    ANNALS OF ONCOLOGY, 2001, 12 (12) : 1749 - 1755
12345